Utilising Graph Machine Learning within Drug Discovery and Development
arXiv:2012.05716
Abstract
Graph Machine Learning (GML) is receiving growing interest within the pharmaceutical and biotechnology industries for its ability to model biomolecular structures, the functional relationships between them, and integrate multi-omic datasets - amongst other data types. Herein, we present a multidisciplinary academic-industrial review of the topic within the context of drug discovery and development. After introducing key terms and modelling approaches, we move chronologically through the drug development pipeline to identify and summarise work incorporating: target identification, design of small molecules and biologics, and drug repurposing. Whilst the field is still emerging, key milestones including repurposed drugs entering in vivo studies, suggest graph machine learning will become a modelling framework of choice within biomedical machine learning.
19 pages, 7 figures, 2 tables
References in corpus (9)
- Semi-Supervised Classification with Graph Convolutional Networks
- Fast Graph Representation Learning with PyTorch Geometric
- RotatE: Knowledge Graph Embedding by Relational Rotation in Complex Space
- Fake News Detection on Social Media using Geometric Deep Learning
- Position-aware Graph Neural Networks
- Drug-Drug Adverse Effect Prediction with Graph Co-Attention
- Few-shot link prediction via graph neural networks for Covid-19 drug-repurposing
- Clique pooling for graph classification
- Relation-weighted Link Prediction for Disease Gene Identification